Committee for Advanced Therapies (CAT)
Minutes of the meeting on 14-16 February 2024

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

Health and safety information
In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers
Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
# Table of contents

## 1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts .......................... 5
1.2. Adoption of agenda ........................................................................................................ 5
1.3. Adoption of the minutes .............................................................................................. 5

## 2. Evaluation of ATMPs

2.1. Opinions .......................................................................................................................... 5
2.2. Oral explanations ............................................................................................................ 5
2.3. Day 180 list of outstanding issues ................................................................................ 6
2.4. Day 120 list of questions .............................................................................................. 6
2.5. Day 80 assessment reports ............................................................................................ 6
2.5.1. Beremagene geperpavec - PRIME - Orphan - EMEA/H/C/006330 ................................. 6
2.6. Update on ongoing initial applications .......................................................................... 6
2.7. New applications ........................................................................................................... 6
2.8. Withdrawal of initial marketing authorisation application .......................................... 6
2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004 .................................................. 6
2.10. Companion diagnostics ............................................................................................... 6
2.10.1. Initial consultation .................................................................................................. 6
2.10.2. Follow-up consultation .......................................................................................... 6
2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 ...................................................................... 7
2.11.1. Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0032 .................................................................................................................. 7
2.11.2. Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0036/G .................................................................................................................. 7
2.11.3. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0021 ................................................................................................. 7
2.11.4. Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0071 ................................ 8
2.11.5. Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0075 ................. 8
2.11.6. Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0079/G ................ 8
2.11.7. Upstaza - Eladocagene exuparvovec - Orphan - EMEA/H/C/005352/II/0013 ........ 9
2.11.8. Tecartus; Yescarta - Axicabtagene ciloleucel; Brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2500 .................................................................................. 9

## 2.12. Extension applications ............................................................................................ 10

## 2.13. Other Post-Authorisation Activities ...................................................................... 10

2.13.1. Abecma - Idecabtagene vicleucel - Orphan - EMEA/H/C/004662/REC/017.1 ............ 10
2.13.2. Abecma - Idecabtagene vicleucel - Orphan - EMEA/H/C/004662/REC/018.1 ............ 10
2.13.3. Upstaza - Eladocagene exuparvovec - Orphan - EMEA/H/C/005352/S/0017 .......... 10
2.13.4. Zolgensma - Onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/P46/022 ........ 10
2.13.5. Luxturna - Voretigene neparvovec - EMEA/H/C/PSUSA/00010742/202307 ...................... 11
2.13.6. Abecma - Idecabtagene viclecucel - Orphan - EMEA/H/C/004662/REC/019.1 .................... 11
2.14. GMP and GCP inspections requests ................................................................. 11

3. Certification of ATMPs 11
3.1. Opinion ................................................................................................................. 11
3.2. Day 60 Evaluation Reports ................................................................................... 11
3.3. New Applications ............................................................................................... 12

4. Scientific Recommendation on Classification of ATMPs 12
4.1. New requests – Appointment of CAT Coordinator .............................................. 12
4.1.1. Allogeneic human induced pluripotent stem cells-derived corneal limbal stem cells .......... 12
4.1.2. Olfactory glial cells isolated from autologous human olfactory bulb, expanded in culture... 12
4.1.3. Circular RNA capable to bind to mutated regions of the messenger RNA from the DMPK gene12
4.2. Day 30 ATMP scientific recommendation ......................................................... 12
4.2.1. Modified measles vaccine virus .......................................................................... 12
4.3. Day 60 revised scientific recommendation (following list of questions) ........... 13
4.4. Finalisation of procedure .................................................................................... 13
4.4.1. Allogeneic expanded natural killer cells .............................................................. 13
4.4.2. Autologous tissue generated in the human body (in vivo) through the foreign body reaction13
4.4.3. Dendritic cells activated by lysate of circulating tumour cells ............................. 13
4.4.4. Autologous T Lymphocytes engineered with nanoparticles with curcumin encapsulated ... 13
4.4.5. Spermatogonial stem cells, propagated in vitro .................................................. 14
4.5. Follow-up and guidance ..................................................................................... 14

5. Scientific Advice 14
5.1. New requests - appointment of CAT Rapporteurs .............................................. 14
5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers ........... 14
5.1.2. Scientific advice procedures starting at the next SAWP meeting ....................... 14
5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs ................................. 15
5.3. Finalisation of D70 procedures – feedback from the discussion meeting .......... 15
5.4. Final Advice Letters for procedures finalised the previous month ..................... 15

6. Pre-Authorisation Activities 15
6.1. Paediatric investigation plans .............................................................................. 15
6.2. ITF briefing meetings in the field of ATMPs ...................................................... 15
6.2.1. Overview of ITF activities in 2023 .................................................................... 15
6.3. Priority Medicines (PRIME) – Eligibility requests ............................................ 15
6.3.1. Month 0 - Start of the procedure ...................................................................... 15
6.3.2. Month 1 – Discussion of eligibility ................................................................. 15
6.3.3. Month 2 – Recommendation of eligibility ................................................................. 15
6.3.4. Ongoing support ...................................................................................................... 16

7. Organisational, regulatory and methodological matters ........................................... 16

7.1. Mandate and organisation of the CAT ................................................................. 16

7.1.1. CAT membership ................................................................................................. 16

7.1.2. Vote by proxy ....................................................................................................... 16

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Belgian presidency – 15-17 May 2024 ................................................................................................................................. 16

7.1.4. CAT Strategic Review & Learning meeting (SRLM) under the Spanish presidency – 26-27 October 2023 ....................................................................................................................... 16

7.2. Coordination with EMA Scientific Committees ....................................................... 16

7.2.1. Minutes and draft agenda - PCWP and HCPWP meetings .................................... 16

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ........ 17

7.3.1. ATMP Quality assessment support group ............................................................. 17

7.3.2. Launch of Call for Nominations to Biological Quality European Specialised Expert Community (ESEC) .................................................................................................................. 17

7.4. Cooperation with the EU regulatory network .......................................................... 17

7.5. Cooperation with international regulators .............................................................. 17

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan) ... 17

7.5.2. International Pharmaceutical Regulatory Programme (IPRP) Gene and Cell therapy working group ..................................................................................................................... 17

7.6. CAT work plan ....................................................................................................... 18

7.6.1. Guideline on quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials .................................................................................................................... 18

7.6.2. CAT Scientific symposium, 8-9 October 2024 ..................................................... 18

7.6.3. CAT - regulatory session at the European Society of Gene & Cell Therapy (ESGCT) 2024 meeting ...................................................................................................................... 18

7.7. Planning and reporting ........................................................................................... 18

7.8. Others .................................................................................................................... 18

7.8.1. Report from Group for Internal Rules on Extensions of Clock Stops ...................... 18

7.8.2. ATMP Support Pilot for academia ...................................................................... 19

7.8.3. CoGenT (Collaboration on Gene Therapies) Pilot ................................................. 19

7.8.4. International Society for cell and gene therapy (ISCT) Annual meeting .............. 19

8. Any other business ...................................................................................................... 19

8.1. IRIS training ............................................................................................................ 19

9. List of participants ..................................................................................................... 20

10. Explanatory notes .................................................................................................... 24
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

The Chairperson opened the meeting by welcoming all participants. The meeting was held in-person with some members connect remotely.

In accordance with the Agency’s policy on handling of declarations of interests of scientific committees’ members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The EMA secretariat announced the names of the Committee members who delegated their vote via proxy and the Committee members who received such proxy.

1.2. **Adoption of agenda**

The CAT agenda for 14-16 February 2024 meeting was adopted with one addition to section 2.13: Abecma - Idecabtagene vicleucel - EMEA/H/C/004662/REC/019.1.

1.3. **Adoption of the minutes**

The CAT minutes for 17-20 January 2024 meeting were adopted.

2. **Evaluation of ATMPs**

2.1. **Opinions**

No items

2.2. **Oral explanations**

No items
2.3. **Day 180 list of outstanding issues**

No items

2.4. **Day 120 list of questions**

No items

2.5. **Day 80 assessment reports**

2.5.1. **Beremagene geperpavec - PRIME - Orphan - EMEA/H/C/006330**

Krystal Biotech Netherlands B.V.; Treatment of patients from birth with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene

Scope: Day 80 assessment report

**Action:** for information

The information was noted.

2.6. **Update on ongoing initial applications**

No items

2.7. **New applications**

No items

2.8. **Withdrawal of initial marketing authorisation application**

No items

2.9. **Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004**

No items

2.10. **Companion diagnostics**

2.10.1. **Initial consultation**

No items

2.10.2. **Follow-up consultation**

No items
2.11. **Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

2.11.1. **Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0032**

Bristol-Myers Squibb Pharma EEIG  
Rapporteur: Concetta Quintarelli  
Scope: Quality, opinion  
**Action:** for adoption  
The opinion was adopted.

2.11.2. **Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0036/G**

Bristol-Myers Squibb Pharma EEIG  
Rapporteur: Concetta Quintarelli  
Scope: Clinical, Request for supplementary information  
Grouped application comprising two variations as follows:  
C.I.4 – Update of sections 4.4 and 4.8 of the SmPC in order to add immune effector cell-associated neurotoxicity syndrome (ICANS) as an adverse drug reaction (ADR) based on the cumulative review of MAH safety database and literature. The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce editorial changes.  
A.6 – To include the ATC Code L01XL08 in section 5.1 of the SmPC.  
**Action:** for adoption  
CAT noted the assessment from the Rapporteur on occurrence of ICANS in clinical trials or reported as ADRs. The request for supplementary information was adopted.

2.11.3. **CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0021**

Janssen-Cilag International NV  
Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays  
Scope: Clinical, opinion  
Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 1 prior therapy, including an IMiD and a PI, have demonstrated disease progression on or after the last therapy and are refractory to lenalidomide for CARVYKTI, based on interim results from study MMY3002 listed as a specific obligation (SOB/006) in the Annex II. This is an ongoing, Phase 3, randomized, open-label, multicentre study to determine whether treatment with cilta-cel provides an efficacy benefit compared to standard therapy in participants with relapsed and lenalidomide-refractory multiple myeloma. As a consequence, sections 4.1, 4.4, 4.5, 4.8,
5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II of the PI. As part of the application the MAH is requesting a 1-year extension of the market protection.

**Action:** for adoption


Lothar Bergman, the chair of the scientific advisory group (SAG) oncology, presented the responses from the SAG experts to the questions asked by the CAT. CAT noted the SAG output.

The Rapporteur presented the assessment of the responses by the MAH. Based on final assessment and responses provided by the SAG, CAT agreed that the benefit risk of Breyanzi is positive for the extension of indication. CAT discussed the wording of the sections 4.4 and 5.1 of the SmPC.

A positive opinion was adopted by CAT. CAT also concluded that the specific obligation is considered fulfilled, therefore the conditional marketing authorisation (MA) can be converted to a full Marketing Authorisation. The specific obligation is converted in a recommendation for the MAH to provide the final study report of study MMY3002.

---

**2.11.4. Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0071**

Novartis Europharm Limited

Rapporteur: Rune Kjeken

Scope: Clinical, Opinion

Update of sections 5.1 and 5.2 of the SmPC in order to update efficacy and pharmacokinetic information based on final results from study CCTLO19B2202 (a phase II, single arm, multicentre trial to determine the efficacy and safety of CTL019 in paediatric patients with relapsed and refractory B-cell acute lymphoblastic leukaemia). Submission of cellular kinetic report for the B-cell acute lymphoblastic leukaemia (ALL) indication based on data from pivotal study CCTLO19B2202 and the supportive study CCTLO19B2205J involving paediatric ALL patients (partially fulfil REC).

In addition, the MAH took this opportunity to introduce editorial changes.

**Action:** for adoption


The Rapporteur presented the assessment of the responses by the MAH. The changes to the SmPC were agreed. The opinion was adopted.

---

**2.11.5. Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0075**

Novartis Europharm Limited

Rapporteur: Rune Kjeken, PRAC Rapporteur: Gabriele Maurer

Scope: Clinical, opinion

Update of sections 5.1 and 5.2 of the SmPC in order to update efficacy and pharmacokinetic
information based on final results from study CCT019C2201 PAES in the Annex II (ANX008); this is a Phase II, single arm, multicentre trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The RMP version 6 has also been submitted. In addition, the MAH took the opportunity to update Annex II.D of the PI.

Action: for adoption


The Rapporteur presented the assessment of the responses by the MAH. The changes to the SmPC were agreed. The opinion was adopted.

2.11.6. **Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0079/G**

Novartis Europharm Limited
Rapporteur: Rune Kjeken
Scope: Quality, opinion

Action: for adoption

The opinion was adopted.

2.11.7. **Upstaza - Eladocagene exuparvovec - Orphan - EMEA/H/C/005352/II/0013**

PTC Therapeutics International Limited
Rapporteur: Joseph DeCourcey
Scope: Quality, opinion

To submit the final report with the results of the active substance and finished product concurrent process validation batches, including hold time data for the finished product batch, in order to further assess process consistency and maintain patient’s safety (Annex II condition).

Action: for adoption

Request for supplementary information adopted on 19.01.2024, 08.09.2023.

The Rapporteur presented the assessment of the responses by the MAH. The opinion was adopted.

2.11.8. **Tecartus; Yescarta - Axicabtagene ciloleucel; Brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2500**

Kite Pharma EU B.V.
Rapporteur: Jan Mueller-Berghaus
Scope: Quality, Request for supplementary information

Action: for adoption

The request for supplementary information was adopted.
2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Abecma - Idecabtagene vicleucel - Orphan - EMEA/H/C/004662/REC/017.1

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Rune Kjeken
Scope: Quality, Request for supplementary information
Action: for adoption
The request for supplementary information was adopted.

2.13.2. Abecma - Idecabtagene vicleucel - Orphan - EMEA/H/C/004662/REC/018.1

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Rune Kjeken
Scope: Quality, fulfilled
Action: for adoption
The report was adopted.

2.13.3. Upstaza - Eladocagene exuparvovec - Orphan - EMEA/H/C/005352/S/0017

PTC Therapeutics International Limited
Rapporteur: Joseph DeCourcey
Scope: Annual Re-assessment, opinion
Action: for adoption
Further to the adoption of variation II/13, CAT adopted a positive opinion for the annual re-assessment.

2.13.4. Zolgensma - Onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/P46/022

Novartis Europharm Limited
Rapporteur: Emmely de Vries
Scope: Clinical, Request for supplementary information
Paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended. Final study report COAV101A12306: Phase IIIb, open-label, single-arm, single-dose, multicentre study evaluating the safety, tolerability, and efficacy of gene
replacement therapy with intravenous OAV101 (AVXS-101) in paediatric patients with spinal muscular atrophy (SMA).

**Action:** for adoption

The Rapporteur presented the assessment of the P46 procedure (final results of a paediatric clinical trial in older and heavier children). The changes to the SmPC section 4.4 and 4.8 were already implemented as part of the post authorisation procedure. A request for supplementary information was adopted.

### 2.13.5. Luxturna - Voretigene neparvovec - EMEA/H/C/PSUSA/00010742/202307

Novartis Europharm Limited  
Rapporteur: Gabriele Maurer  
Scope: PRAC recommendation  
**Action:** for adoption

The PRAC recommendation was adopted.

### 2.13.6. Abecma - Idecabtagene vicleucel - Orphan - EMEA/H/C/004662/REC/019.1

Bristol-Myers Squibb Pharma EEIG  
Rapporteur: Rune Kjeken  
Scope: Quality, fulfilled  
**Action:** for adoption

The report was adopted.

### 2.14. GMP and GCP inspections requests

No items

### 3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

#### 3.1. Opinion

No items

#### 3.2. Day 60 Evaluation Reports

No items
3.3. **New Applications**

No items

---

4. **Scientific Recommendation on Classification of ATMPs**

**Timetable:**
- Start of the procedure: 19.02.2024
- EMA Coordinator’s draft report: 01.03.2024
- CAT Coordinator’s comments: 06.03.2024
- Revised scientific recommendation: 08.03.2024
- CAT’s discussion of scientific recommendation: 15.03.2024

---

4.1. **New requests – Appointment of CAT Coordinator**

4.1.1. **Allogeneic human induced pluripotent stem cells-derived corneal limbal stem cells**

For treatment of limbal stem cell deficiency

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT coordinator was appointed.

4.1.2. **Olfactory glial cells isolated from autologous human alfactory bulb, expanded in culture**

For treatment of complete spinal cord injuries

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT coordinator was appointed.

4.1.3. **Circular RNA capable to bind to mutated regions of the messenger RNA from the DMPK gene**

For treatment of myotonic dystrophy type 1

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT coordinator was appointed.

4.2. **Day 30 ATMP scientific recommendation**

4.2.1. **Modified measles vaccine virus**

For the treatment of solid cancer tumours
Committee for Advanced Therapies (CAT)
EMA/CAT/185591/2024

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 01.03.2024.

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Allogeneic expanded natural killer cells

For the treatment of acute myeloid leukaemia

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a somatic cell therapy medicinal product as provided in Article 2(1) of Regulation (EC) No. 1394/2007.

4.4.2. Autologous tissue generated in the human body (in vivo) through the foreign body reaction

For tissue augmentation

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does not fulfil the definition of an advanced therapy medical product as provided in Article 2(1) of Regulation (EC) No. 1394/2007.

4.4.3. Dendritic cells activated by lysate of circulating tumour cells

For the treatment of solid tumours in metastatic stage

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a somatic cell therapy medicinal product as provided in Article 2(1) of Regulation (EC) No. 1394/2007.

4.4.4. Autologous T Lymphocytes engineered with nanoparticles with curcumin incapsulated

For the treatment of melanoma

Scope: European Commission raised no comments. ATMP
scientific recommendation

**Action:** for adoption

The classification report was adopted. The product does fulfil the definition of a somatic cell therapy medicinal product and a combined ATMP as provided in Article 2(1) of Regulation (EC) No. 1394/2007.

### 4.4.5. Spermatogonial stem cells, propagated *in vitro*

Male infertility due to gonadotoxic treatment

**Scope:** Procedure on hold pending input/comments from the European Commission

**Action:** for information

The information was noted.

### 4.5. Follow-up and guidance

No items

### 5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

#### 5.1. New requests - appointment of CAT Rapporteurs

##### 5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

<table>
<thead>
<tr>
<th>Timetable</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start of procedure at SAWP:</td>
<td>05-08.02.2024</td>
</tr>
<tr>
<td>Appointment of CAT Peer Reviewers:</td>
<td>14-16.02.2024</td>
</tr>
<tr>
<td>SAWP first reports:</td>
<td>26.02.2024</td>
</tr>
<tr>
<td>CAT Peer Reviewer comments (NC/C):</td>
<td>01.03.2024</td>
</tr>
<tr>
<td>CAT Peer Reviewer comments (Q):</td>
<td>06.02.2024</td>
</tr>
<tr>
<td>Discussion at SAWP:</td>
<td>04-07.03.2024</td>
</tr>
<tr>
<td>Discussion at CAT and feedback to SAWP:</td>
<td>13-15.03.2024</td>
</tr>
</tbody>
</table>

##### 5.1.2. Scientific advice procedures starting at the next SAWP meeting

<table>
<thead>
<tr>
<th>Timetable</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start of procedure at SAWP:</td>
<td>04-07.03.2024</td>
</tr>
<tr>
<td>Appointment of CAT Peer Reviewers:</td>
<td>13-15.03.2024</td>
</tr>
<tr>
<td>SAWP first reports:</td>
<td>02.04.2024</td>
</tr>
<tr>
<td>CAT Peer Reviewer comments (NC/C):</td>
<td>05.04.2024</td>
</tr>
<tr>
<td>CAT Peer Reviewer comments (Q):</td>
<td>10.04.2024</td>
</tr>
<tr>
<td>Discussion at SAWP:</td>
<td>08-11.04.2024</td>
</tr>
<tr>
<td>Discussion at CAT and feedback to SAWP:</td>
<td>17-19.04.2024</td>
</tr>
</tbody>
</table>

No items
5.2. Procedures discussed at SAWP – 1st reports, D40 JRIs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.2.1. Overview of ITF activities in 2023

ITF Coordinator: Oriane Blanquie
Scope: Summary of main activities conducted by ITF in 2023
Action: for information

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:
Procedure start: 05-08.02.2024
SAWP recommendation: 07.03.2024
CAT recommendation: 15.03.2024
CHMP adoption of report and final recommendation: 21.03.2024

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility
6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

**Action:** for information

None

7.1.2. Vote by proxy

**Action:** for information

Nancy de Bremaeker (Luxembourg) gave a proxy to Claire Beuneu (Belgium) to vote on behalf of Nancy de Bremaeker during the entire meeting.

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Belgian presidency – 15-17 May 2024

CAT: Claire Beuneu
Scope: Draft agenda of the upcoming SRLM
**Action:** for discussion

The draft agenda of the upcoming CAT SRLM and CAT-PDCO joint SRLM was presented.

7.1.4. CAT Strategic Review & Learning meeting (SRLM) under the Spanish presidency – 26-27 October 2023

CAT: Sol Ruiz, Marcos Timon
Scope: Final minutes of the SRLM meeting
**Action:** for information

The final minutes of the SRLM meeting were noted.

7.2. Coordination with EMA Scientific Committees

7.2.1. Minutes and draft agenda - PCWP and HCPWP meetings

Scope: Minutes and draft agenda for the PCWP and HCPWP meetings

**Action:** for information

The minutes and draft agenda for the PCWP and HCPWP meetings of 27-28 February 2024 were noted.
7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. ATMP Quality assessment support group

Scope: To inform the CAT members on the creation of the group of ATMP Quality experts to be contacted to give informal advice and act as sounding board for member states in relation to assessment of quality aspects of ATMPs

Action: for information

EMA provided information on the ATMP quality assessment support group and on the procedure to contact the members of this group on quality related assessment questions.

7.3.2. Launch of Call for Nominations to Biological Quality European Specialised Expert Community (ESEC)

Scope: Mandate and rules of procedure

Action: for adoption

EMA presented the mandate and rules of biological quality European Specialised Expert Community (ESEC). The mandate and rules of procedure were adopted.

CAT members with quality expertise will be automatically included in this group, unless if they want to opt out.

7.4. Cooperation with the EU regulatory network

No items

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

CAT: Ilona Reischl

Scope: Agenda of the teleconference of 22.02.2024

Action: for information

The agenda of the upcoming ATMP cluster was noted.

7.5.2. International Pharmaceutical Regulatory Programme (IPRP) Gene and Cell therapy working group

CAT: Pille Säälik

Scope: Agenda of the teleconference of 27.02.2024

Action: for information

The agenda of the upcoming IPRP Gene and Cell therapy working group was noted.
7.6. **CAT work plan**

7.6.1. **Guideline on quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials**

CAT: Ilona Reischl

Scope: Draft guideline, updated following the external consultation

**Action:** for adoption for release for external consultation

EMA presented the status of the guideline: comments from member states and EDQM were received on the guideline, which are being discussed by the drafting group members. The pre-final guideline will now be sent to the clinical trial coordination group (CTCG) for consultation. Member states/CAT members can provide final comments by the same deadline. The guideline will be adopted by CAT members via written procedure and will be presented at CHMP PROM March 2024 meeting for adoption. This will allow publication on the external website in the March 2024, for a short second public consultation until end of May 2024.

7.6.2. **CAT Scientific symposium, 8-9 October 2024**

CAT Chair: Ilona Reischl

Scope: draft programme

**Action:** for discussion

EMA provided a short update on the activities to be performed in drafting the programme.

7.6.3. **CAT - regulatory session at the European Society of Gene & Cell Therapy (ESGCT) 2024 meeting**

CAT Chair: Ilona Reischl

Scope: To discuss topics on CAT and EMA activities to support developers, progress and challenges in ATMP development for CAT session on ATMP regulatory aspects at the ESGCT meeting that takes place on 22-25 October 2024 in Rome, Italy

**Action:** for discussion

CAT agreed to hold a regulatory session at the ESGCT annual meeting.

7.7. **Planning and reporting**

No items

7.8. **Others**

7.8.1. **Report from Group for Internal Rules on Extensions of Clock Stops**

CAT: Olga Kholmanskikh
Scope: Report on outcomes and proposals to the CHMP. Comments to be sent by 29 February 2024

**Action:** for discussion

EMA presented the outcome and proposals that came out of the discussion in the Group for Internal Rules on Extensions of Clock Stops. The proposals were agreed. CAT indicated that it is important that the stricter application of the clock stop rules is communicated externally to the medicines’ developers.

### 7.8.2. ATMP Support Pilot for academia

Scope: Update and information on selected candidates

**Action:** for information

EMA provided an update on the two additional candidate products that were selected for the pilot. Next steps were presented.

### 7.8.3. CoGenT (Collaboration on Gene Therapies) Pilot

Scope: Internal collaboration of regulatory authorities to facilitate the development of gene therapies for orphan diseases

**Action:** for information

EMA presented to CAT the CoGenT pilot that has been initiated by FDA. This would be a global collaboration of ICH founding members on scientific advice and evaluation of orphan gene therapies. The way of interactions (when and how) still needs to be defined.

CAT asked for the Rapporteurs of products to be included in the pilot to be consulted in advance.

### 7.8.4. International Society for cell and gene therapy (ISCT) Annual meeting

CAT: Ilona Reischl

Scope: Invitation to attend the 2nd Annual Global Regulators Summit (28 May 2024) and the panel discussion on Regulatory Considerations for Platform-based Cell and Gene Therapy (29 May 2024)

**Action:** for agreement

CAT agreed for Pille Säälik to attend the ISCT meeting to represent the CAT.

### 8. Any other business

#### 8.1.1. IRIS training

Scope: Training on the use of IRIS and the new implementation of communication process between CAT Secretariat and Committee participants
**Action**: for information

EMA provided a follow-up training to CAT on the use of IRIS.

Date of next CAT meeting:
13-15 March 2024

### 9. List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the February 2024 CAT meeting, which was held in-person.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Member State or affiliation</th>
<th>Outcome restriction following evaluation of e-DoI</th>
<th>Topics on agenda for which restrictions apply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ilona Reischl</td>
<td>Chair</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Silke Dorner</td>
<td>Member</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Claire Beuneu</td>
<td>Member</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Olga Kholmanskikh</td>
<td>Alternate</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rozalina Kulaksazova</td>
<td>Member</td>
<td>Bulgaria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Azra Selimovic</td>
<td>Member</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Petra Sokol</td>
<td>Alternate</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rafaella Pontou</td>
<td>Member</td>
<td>Cyprus</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kristyna Rehorova Hradilkova</td>
<td>Alternate</td>
<td>Czechia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ebru Karakoc Madsen</td>
<td>Member</td>
<td>Denmark</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Bibi Fatima Syed Shah</td>
<td>Alternate</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Toivo Maimets</td>
<td>Member</td>
<td>Estonia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Pille Saalik</td>
<td>Alternate</td>
<td>Estonia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Heli Suila</td>
<td>Member</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Violaine Closson Carella</td>
<td>Member</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------------</td>
<td>----------------------</td>
<td>---------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Jean-Michel Race</td>
<td>Alternate</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jan Mueller-Berghaus</td>
<td>Member (CHMP co-opted member)</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Egbert Flory</td>
<td>Alternate (to CHMP representative)</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Gazouli</td>
<td>Member</td>
<td>Greece</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Angeliki Rompoti</td>
<td>Alternate</td>
<td>Greece</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Anna Katalin Barane Gilicze</td>
<td>Member</td>
<td>Hungary</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Viola Bardoczy</td>
<td>Alternate</td>
<td>Hungary</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Joseph De Courcey</td>
<td>Member</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Richard Carroll</td>
<td>Alternate</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Concetta Quintarelli</td>
<td>Member</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Barbara Bonamassa</td>
<td>Alternate</td>
<td>Italy</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Una Riekstina</td>
<td>Member</td>
<td>Latvia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Villma Perikaite</td>
<td>Member (CHMP member)</td>
<td>Lithuania</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Nancy De Bremaeker</td>
<td>Alternate</td>
<td>Luxembourg</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>John J. Borg</td>
<td>Member (CHMP member)</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Anthony Samuel</td>
<td>Alternate (to CHMP representative)</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Emmely de Vries</td>
<td>Member</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Berendina Maria (Tineke) van den Hoorn</td>
<td>Alternate</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rune Kjeken</td>
<td>Member</td>
<td>Norway</td>
<td>No restrictions</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------------------------------------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Dariusz Sladowski</td>
<td>Member</td>
<td>Poland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Maria Isabel Borba Vieira</td>
<td>Alternate (to CHMP representative)</td>
<td>Portugal</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Margareta Fogelová</td>
<td>Alternate</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Suzana Vidic</td>
<td>Alternate</td>
<td>Slovenia</td>
<td>No participation in final deliberations and voting on:</td>
<td>2.11.4; 2.11.5 Kymriah 2.13.4 Zolgensma</td>
</tr>
<tr>
<td>Sol Ruiz</td>
<td>Member (CHMP co-opted member)</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Marcos Timón</td>
<td>Alternate (to CHMP representative)</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Luttgen</td>
<td>Member</td>
<td>Sweden</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Charlotte Anderberg</td>
<td>Alternate</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Bernd Gansbacher</td>
<td>Alternate</td>
<td>Clinicians' Representative</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Alessandra Renieri</td>
<td>Alternate</td>
<td>Clinicians' Representative</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Kerstin Sollerbrant Melefors</td>
<td>Member</td>
<td>Patients' Representative</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Mencia de Lemus Belmonte</td>
<td>Alternate</td>
<td>Patients' Representative</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Kieran Breen</td>
<td>Member (Vice-Chair)</td>
<td>Patients' Representative</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Federica Chiara</td>
<td>Alternate</td>
<td>Patients' Representative</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Torjorn Callreus</td>
<td>Expert</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Lothar Bergmann</td>
<td>Guest</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-------</td>
<td>----------------------------</td>
<td>---------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Odoardo Maria Olimpieri</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Antonella Isgro</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Federico de Angelis</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Joao Manuel Lopez de Oliveira</td>
<td>Expert</td>
<td>Portugal</td>
<td>No interests declared with information under any other interests</td>
<td></td>
</tr>
<tr>
<td>Angelo Ferreira da Silva</td>
<td>Expert</td>
<td>Portugal</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Attila Sebe</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
</tbody>
</table>
10. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

For a list of acronyms and abbreviations, see:
List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in relation to EMA’s regulatory activities

**Evaluation of ATMPs (section 2)**

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

**New applications (sections 2.1. to 2.9.)**

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

![Evaluation of ATMPs diagram](#)

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 **(Ongoing evaluation procedures)** (section 2.3). Section 2.6 also includes the CAT discussions at any other point of the evaluation procedure of new applications.

**Oral explanation (section 2.2.)**

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

**New applications (section 2.7.)**

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.
**Withdrawal of applications (section 2.8.)**

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

**Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)**

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

**Companion diagnostics (section 2.10)**

This section lists applications for initial and follow-on consultation of companion diagnostics.

**Post-authorisation activities (section 2.11-2.13.)**

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, quality defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

**GMP and GCP Inspections Issues (section 2.14.)**

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

**Certification of ATMPs (section 3)**

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

**Scientific Recommendation on Classification of ATMPs (Section 4)**

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

**Scientific Advice (section 5)**

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

**Pre-Authorisation (section 6)**

**Paediatric Investigation Plan (PIP)**

This section includes the discussion of an ATMP before a formal application for marketing authorisation.
is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

**ITF Briefing meeting in the field of ATMPs**

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT.

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](http://www.ema.europa.eu/).

**Priority Medicines (PRIME)**

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

**Organisational, regulatory and methodological matters (section 7)**

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

**Any other business (section 8)**

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/).